Millennium Velcade launch
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Shipments of Millennium's proteasome inhibitor Velcade (bortezomib) begin the week of May 19 following accelerated approval May 13 for "treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy." Approval is based on Phase II data from the 202-patient SUMMIT trial and the 54-patient CREST study (1Pharmaceutical Approvals Monthly Feb. 1, p. 9)...
You may also be interested in...
Millennium Expects Velcade Accelerated Approval In ’03: Is Phase II Enough?
Millennium is confident that its multiple myeloma treatment Velcade (bortezomib, formerly PS-341) will receive accelerated approval on the basis of Phase II trials in its Jan. 21 NDA submission.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.